Long‐term effects of crizotinib in ALK‐positive tumors (excluding NSCLC): A phase 1b open‐label study

Crizotinib, an inhibitor of anaplastic lymphoma kinase (ALK), MET, and ROS1, is approved for treatment of patients with ALK‐positive or ROS1‐positive advanced non‐small‐cell lung cancer (NSCLC). However, ALK rearrangements are also implicated in other malignancies, including anaplastic large‐cell ly...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Am J Hematol
Egile Nagusiak: Gambacorti‐Passerini, Carlo, Orlov, Sergey, Zhang, Li, Braiteh, Fadi, Huang, Huiqiang, Esaki, Taito, Horibe, Keizo, Ahn, Jin‐Seok, Beck, Joseph T., Edenfield, William Jeffrey, Shi, Yuankai, Taylor, Matthew, Tamura, Kenji, Van Tine, Brian A., Wu, Shang‐Ju, Paolini, Jolanda, Selaru, Paulina, Kim, Tae Min
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: John Wiley and Sons Inc. 2018
Gaiak:
Research Articles
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5947833/
https://ncbi.nlm.nih.gov/pubmed/29352732
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ajh.25043
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak